These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20980681)

  • 1. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.
    Struyf S; Salogni L; Burdick MD; Vandercappellen J; Gouwy M; Noppen S; Proost P; Opdenakker G; Parmentier M; Gerard C; Sozzani S; Strieter RM; Van Damme J
    Blood; 2011 Jan; 117(2):480-8. PubMed ID: 20980681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase.
    Van Raemdonck K; Gouwy M; Lepers SA; Van Damme J; Struyf S
    Angiogenesis; 2014 Jul; 17(3):631-40. PubMed ID: 24469069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47-70) and CXCL4L1(47-70) in an EGF-dependent breast cancer model.
    Van Raemdonck K; Berghmans N; Vanheule V; Bugatti A; Proost P; Opdenakker G; Presta M; Van Damme J; Struyf S
    Oncotarget; 2014 Nov; 5(21):10916-33. PubMed ID: 25373734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis.
    Struyf S; Burdick MD; Peeters E; Van den Broeck K; Dillen C; Proost P; Van Damme J; Strieter RM
    Cancer Res; 2007 Jun; 67(12):5940-8. PubMed ID: 17575164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitment.
    Sarabi A; Kramp BK; Drechsler M; Hackeng TM; Soehnlein O; Weber C; Koenen RR; Von Hundelshausen P
    J Thromb Haemost; 2011 Jan; 9(1):209-19. PubMed ID: 20961394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.
    Vandercappellen J; Liekens S; Bronckaers A; Noppen S; Ronsse I; Dillen C; Belleri M; Mitola S; Proost P; Presta M; Struyf S; Van Damme J
    Mol Cancer Res; 2010 Mar; 8(3):322-34. PubMed ID: 20215425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative distribution and biological characterization of CXCL4L1 isoforms in platelets from healthy donors.
    Ruytinx P; Janssens R; Berghmans N; Gouwy M; Ronsse I; Liekens S; Proost P; Van Damme J; Struyf S
    Biochem Pharmacol; 2017 Dec; 145():123-131. PubMed ID: 28859966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Properties of CXCL4L1 and Its Recognition of the CXCR3 N-Terminus.
    Liu YH; Chuang CH; Lee YZ; Lee ET; Lo CL; Wu CY; Huang LK; Bikfalvi A; Sue SC
    Biochemistry; 2023 Feb; 62(3):722-734. PubMed ID: 36626574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
    Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
    J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells.
    Vandercappellen J; Noppen S; Verbeke H; Put W; Conings R; Gouwy M; Schutyser E; Proost P; Sciot R; Geboes K; Opdenakker G; Van Damme J; Struyf S
    J Leukoc Biol; 2007 Dec; 82(6):1519-30. PubMed ID: 17827342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR3 ligands in disease and therapy.
    Van Raemdonck K; Van den Steen PE; Liekens S; Van Damme J; Struyf S
    Cytokine Growth Factor Rev; 2015 Jun; 26(3):311-27. PubMed ID: 25498524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL4 and CXCL4L1 Differentially Affect Monocyte Survival and Dendritic Cell Differentiation and Phagocytosis.
    Gouwy M; Ruytinx P; Radice E; Claudi F; Van Raemdonck K; Bonecchi R; Locati M; Struyf S
    PLoS One; 2016; 11(11):e0166006. PubMed ID: 27828999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle.
    Dinsart C; Pervolaraki K; Stroh-Dege A; Lavie M; Ronsse I; Rommelaere J; Van Damme J; Van Raemdonck K; Struyf S
    Hum Gene Ther; 2017 Mar; 28(3):295-306. PubMed ID: 28042949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3.
    Mueller A; Meiser A; McDonagh EM; Fox JM; Petit SJ; Xanthou G; Williams TJ; Pease JE
    J Leukoc Biol; 2008 Apr; 83(4):875-82. PubMed ID: 18174362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis.
    Struyf S; Burdick MD; Proost P; Van Damme J; Strieter RM
    Circ Res; 2004 Oct; 95(9):855-7. PubMed ID: 15459074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Roles for CXCL4 Chemokines and CXCR3 in Angiogenesis and Invasion of Pancreatic Cancer.
    Quemener C; Baud J; Boyé K; Dubrac A; Billottet C; Soulet F; Darlot F; Dumartin L; Sire M; Grepin R; Daubon T; Rayne F; Wodrich H; Couvelard A; Pineau R; Schilling M; Castronovo V; Sue SC; Clarke K; Lomri A; Khatib AM; Hagedorn M; Prats H; Bikfalvi A
    Cancer Res; 2016 Nov; 76(22):6507-6519. PubMed ID: 27634764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer.
    Vandercappellen J; Van Damme J; Struyf S
    Cytokine Growth Factor Rev; 2011 Feb; 22(1):1-18. PubMed ID: 21111666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Effects of Platelet Factor 4 (CXCL4) and Its Non-Allelic Variant (CXCL4L1) on Cultured Human Vascular Smooth Muscle Cells.
    Kaczor DM; Kramann R; Hackeng TM; Schurgers LJ; Koenen RR
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR3, a double-edged sword in tumor progression and angiogenesis.
    Billottet C; Quemener C; Bikfalvi A
    Biochim Biophys Acta; 2013 Dec; 1836(2):287-95. PubMed ID: 23994549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL4 and CXCL4L1 in cancer.
    Ruytinx P; Proost P; Struyf S
    Cytokine; 2018 Sep; 109():65-71. PubMed ID: 29903575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.